Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Sherry Martin"'
Autor:
Jessica B Jordan, Louis S. Matza, Kristina S. Boye, Sherry Martin, O. Adetunji, Sarah E Curtis
Publikováno v:
Current Medical Research and Opinion. 32:857-864
Objectives Glucagon-like peptide-1 (GLP-1) receptor agonists have been used to treat type 2 diabetes for almost a decade, and new treatments in this class have recently been introduced. The purpose of this study was to examine perceptions of GLP-1 re
Autor:
Paolo Pozzilli, Jeremie Lebrec, CS Nanette, Zvonko Milicevic, Sudha S. Shankar, Richard David Leslie, Imre Pavo, Sherry Martin, Raffaella Buzzetti, Anne L. Peters
Publikováno v:
Diabetologie und Stoffwechsel.
Autor:
Sherry Martin, Ann Connery
Publikováno v:
Journal of Diabetes Science and Technology
The insulin content in vials/cartridges should be 95 U/ml upon release. No independent confirmation of insulin concentration is available when purchased in the pharmacy (end of the cold supply chain). We quantitatively measured intact insulin in rand
Autor:
Carcary, Marian1 Marian.carcary@nuim.ie, Sherry, Martin1 Martin.sherry@nuim.ie, McLaughlin, Stephen1 Stephen.mclaughlin@nuim.ie, O'Brien, Conor1 Conor.obrien@nuim.ie
Publikováno v:
Proceedings of the European Conference on Management, Leadership & Governance. 2012, p80-87. 8p.
Autor:
Sherry Martin Murphy
Publikováno v:
Japanese Political Science Review. 2:19-37
Autor:
Sudha S. Shankar, Zvonko Milicevic, Jeremie Lebrec, Anne L. Peters, Sherry Martin, Raffaella Buzzetti, Paolo Pozzilli, Richard David Leslie, Imre Pavo, Nanette C. Schloot
Publikováno v:
Diabetes, Obesity and Metabolism. 20:2319-2320
Autor:
Sherry Martin Murphy
Publikováno v:
The Journal of Japanese Studies. 39:441-444
Publikováno v:
Diabetes, obesitymetabolism. 18(10)
Aim To conduct a substudy, using 24-hour continuous glucose monitoring (CGM), of the AWARD-4 trial, which was designed to compare insulin + glucagon-like peptide-1 receptor agonist treatment with an insulin-only regimen. Methods The AWARD-4 trial ran
Publikováno v:
Expert Opinion on Investigational Drugs. 21:1463-1474
Glucagon-like peptide-1 (GLP-1) receptor agonists have been used in clinical management of type 2 diabetes since 2005. Currently approved agents were initially developed and approved for combination therapy with oral antidiabetic drugs (OADs). The po
Autor:
Stephen Hippler, John B. Buse, Sherry Martin, Honghua H. Jiang, Sylvia K. Shenouda, William H. Herman, Bruce H. R. Wolffenbuttel, Jessie L. Fahrbach
Publikováno v:
Diabetes Care. 34:249-255
OBJECTIVE This study compared the durability of glycemic control of twice-daily insulin lispro mix 75/25 (LM75/25: 75% insulin lispro protamine suspension/25% lispro) and once-daily insulin glargine, added to oral antihyperglycemic drugs in type 2 di